Global Peptide Drug Conjugates Market Size study & Forecast, by Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products) by Type (Therapeutic, Diagnostic) and Regional Analysis, 2022-2029

Global Peptide Drug Conjugates Market Size study & Forecast, by Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products) by Type (Therapeutic, Diagnostic) and Regional Analysis, 2022-2029

Global Peptide Drug Conjugates Market is valued at approximately USD 596.27 million in 2021 and is anticipated to grow with a healthy growth rate of more than 18.58% over the forecast period 2022-2029. Peptide–drug conjugates are organic molecules composed of a small drug molecule, a peptide, and a linker. The drug molecule is necessary for the biological activity aids in targeted administration and helps in the enhance the effectiveness of treatment and frequently minimizing undesirable side effects. The increasing expenditure on clinical trial, favorable reimbursement policies, coupled with the rising expenditure on the development of the healthcare facilities are the primary factors that are attributing towards the market growth around the world.

The rising incidences of cancer and related mortality is fueling the demand for peptide drug conjugates for the treatment of the target diseases. The National Cancer Institute, the number of cancer patients is projected to rise to 29.5 million cases by the year 2040 from 18.1 million cases in the year 2018. Accordingly, as per the National Cancer Institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. Thus, these aforementioned factors are exhibiting a positive influence on the growth of the market. Moreover, a strong product pipeline, as well as the growing R&D investment are presenting various lucrative opportunities over the forecasting years. However, the slow clinical development process and major drawback associated with such small molecules are hindering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Peptide Drug Conjugates Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about availability of treatment options, along with the rising government initiatives and favorable reimbursement policies. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the increasing incidences of cancer and related mortality, as well as growing investments to develop and commercialize such novel delivery systems in the market space.

Major market players included in this report are:
Novartis AG
Oncopeptides AB
Bicycle Therapeutics
AstraZeneca
Cybrexa Therapeutics
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies
Pfizer Inc.
Validus Pharmaceuticals LLC

Recent Developments in the Market:
 In November 2022, Cybrexa Therapeutics and Exelixis, Inc. unveiled the company collaborative agreement to offer Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. The main objective of this initiative is likely to expand its clinical pipeline for the targeted drug therapy.
 In June 2019, Novartis AG and PeptiDream Inc. entered a strategic collaboration in order to develop PDC, macrocyclic peptide for diagnostic and therapeutic applications.


Global Peptide Drug Conjugates Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Product:
Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products
By Type:
Therapeutic
Diagnostic

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Novartis AG
Oncopeptides AB
Bicycle Therapeutics
AstraZeneca
Cybrexa Therapeutics
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies
Pfizer Inc.
Validus Pharmaceuticals LLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.